302 related articles for article (PubMed ID: 36158238)
21. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA MAPKAPK5-AS1/PLAGL2/HIF-1α signaling loop promotes hepatocellular carcinoma progression.
Wang L; Sun L; Liu R; Mo H; Niu Y; Chen T; Wang Y; Han S; Tu K; Liu Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):72. PubMed ID: 33596983
[TBL] [Abstract][Full Text] [Related]
23. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
24. Effect of Glut-1 and HIF-1α double knockout by CRISPR/CAS9 on radiosensitivity in laryngeal carcinoma via the PI3K/Akt/mTOR pathway.
Bao YY; Zhong JT; Shen LF; Dai LB; Zhou SH; Fan J; Yao HT; Lu ZJ
J Cell Mol Med; 2022 May; 26(10):2881-2894. PubMed ID: 35415942
[TBL] [Abstract][Full Text] [Related]
25. Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells.
Jiang Y; Bi Y; Zhou L; Zheng S; Jian T; Chen J
BMC Complement Med Ther; 2024 Jan; 24(1):68. PubMed ID: 38297301
[TBL] [Abstract][Full Text] [Related]
26. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
27. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Teng Z; Xu S; Lei Q
Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
[TBL] [Abstract][Full Text] [Related]
28. SOCS5 knockdown suppresses metastasis of hepatocellular carcinoma by ameliorating HIF-1α-dependent mitochondrial damage.
Luo D; Wang Y; Zhang M; Li H; Zhao D; Li H; Chen X; Jin C; Han B
Cell Death Dis; 2022 Nov; 13(11):918. PubMed ID: 36319626
[TBL] [Abstract][Full Text] [Related]
29. Jiedu Sangen decoction inhibits chemoresistance to 5-fluorouracil of colorectal cancer cells by suppressing glycolysis via PI3K/AKT/HIF-1α signaling pathway.
Sun LT; Zhang LY; Shan FY; Shen MH; Ruan SM
Chin J Nat Med; 2021 Feb; 19(2):143-152. PubMed ID: 33641785
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Sui W; Zhang Y; Wang Z; Wang Z; Jia Q; Wu L; Zhang W
Oncol Rep; 2014 May; 31(5):2252-60. PubMed ID: 24647425
[TBL] [Abstract][Full Text] [Related]
31. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways.
Fu J; Chen Y; Cao J; Luo T; Qian YW; Yang W; Ren YB; Su B; Cao GW; Yang Y; Yan YQ; Shen F; Wu MC; Feng GS; Wang HY
Hepatology; 2011 Jan; 53(1):181-92. PubMed ID: 21254169
[TBL] [Abstract][Full Text] [Related]
32. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
34. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1α and glycolysis, by inhibiting PI3K/Akt signaling pathway.
Wang H; Zhao L; Zhu LT; Wang Y; Pan D; Yao J; You QD; Guo QL
Mol Carcinog; 2014 Feb; 53 Suppl 1():E107-18. PubMed ID: 23761018
[TBL] [Abstract][Full Text] [Related]
35. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway.
Yan H; Jung KH; Kim J; Rumman M; Oh MS; Hong SS
Biomed Pharmacother; 2018 Feb; 98():134-141. PubMed ID: 29253760
[TBL] [Abstract][Full Text] [Related]
36. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α.
Cai TY; Liu XW; Zhu H; Cao J; Zhang J; Ding L; Lou JS; He QJ; Yang B
Mol Cancer Ther; 2014 Mar; 13(3):630-42. PubMed ID: 24362462
[TBL] [Abstract][Full Text] [Related]
37. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
38. Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70/HIF-1α.
Wan J; Wu W; Huang Y; Ge W; Liu S
Oncol Rep; 2016 Aug; 36(2):659-68. PubMed ID: 27278081
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
[TBL] [Abstract][Full Text] [Related]
40. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
